See more : Western New England Bancorp, Inc. (WNEB) Income Statement Analysis – Financial Results
Complete financial analysis of Milestone Scientific Inc. (MLSS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Milestone Scientific Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Athena Consumer Acquisition Corp. (ACAQ) Income Statement Analysis – Financial Results
- Hi-Lex Corporation (7279.T) Income Statement Analysis – Financial Results
- Pitti Engineering Limited (PITTIENG.NS) Income Statement Analysis – Financial Results
- MaxLinear, Inc. (MXL) Income Statement Analysis – Financial Results
- Linde plc (LIN.SW) Income Statement Analysis – Financial Results
Milestone Scientific Inc. (MLSS)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
Website: https://www.milestonescientific.com
About Milestone Scientific Inc.
Milestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.83M | 8.81M | 10.30M | 5.44M | 8.37M | 9.62M | 11.28M | 10.48M | 9.49M | 10.33M | 10.01M | 8.65M | 8.38M | 9.75M | 8.55M | 6.62M | 6.39M | 5.84M | 6.43M | 4.75M | 3.97M | 4.07M | 4.09M | 5.67M | 2.86M | 8.80M | 2.90M | 300.00K |
| Cost of Revenue | 3.03M | 3.91M | 3.99M | 1.82M | 2.66M | 5.19M | 4.31M | 4.18M | 3.05M | 3.63M | 3.20M | 3.06M | 3.02M | 3.53M | 3.46M | 2.68M | 2.90M | 3.04M | 2.52M | 2.42M | 2.00M | 1.98M | 1.97M | 2.91M | 839.46K | 9.60M | 1.60M | 0.00 |
| Gross Profit | 6.79M | 4.90M | 6.31M | 3.62M | 5.72M | 4.43M | 6.97M | 6.31M | 6.44M | 6.70M | 6.81M | 5.59M | 5.36M | 6.22M | 5.09M | 3.94M | 3.49M | 2.81M | 3.91M | 2.34M | 1.97M | 2.09M | 2.12M | 2.77M | 2.02M | -800.00K | 1.30M | 300.00K |
| Gross Profit Ratio | 69.12% | 55.65% | 61.25% | 66.60% | 68.28% | 46.05% | 61.77% | 60.16% | 67.88% | 64.86% | 68.05% | 64.66% | 63.99% | 63.78% | 59.55% | 59.52% | 54.65% | 48.06% | 60.81% | 49.15% | 49.56% | 51.38% | 51.80% | 48.75% | 70.60% | -9.09% | 44.83% | 100.00% |
| Research & Development | 701.38K | 1.15M | 878.21K | 307.85K | 189.92K | 245.64K | 272.75K | 1.27M | 100.86K | 88.24K | 191.35K | 181.98K | 140.05K | 270.49K | 241.32K | 168.52K | 397.35K | 1.01M | 286.26K | 187.99K | 131.02K | 147.71K | 49.94K | 386.25K | 455.33K | 400.00K | 1.00M | 200.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.65M | 11.93M | 11.55M | 9.40M | 7.40M | 5.53M | 5.93M | 6.45M | 6.65M | 6.95M | 5.50M | 6.34M | 5.33M | 6.79M | 5.16M | 3.57M | 3.59M | 5.27M | 8.50M | 7.01M | 9.30M | 7.70M | 2.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 51.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.14M | 12.51M | 12.74M | 10.77M | 9.53M | 10.65M | 11.93M | 11.55M | 9.40M | 7.40M | 5.53M | 5.93M | 6.45M | 6.65M | 6.95M | 5.50M | 6.34M | 5.33M | 6.79M | 5.16M | 3.57M | 3.59M | 5.27M | 8.50M | 7.01M | 9.30M | 7.70M | 2.20M |
| Other Expenses | 61.91K | 63.76K | 73.84K | -24.79K | -10.41K | -7.23K | -4.93K | -5.09K | -5.35K | 0.00 | 17.54K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 26.07K | 0.00 | 718.62K | 732.86K | 500.00K | 300.00K | 200.00K |
| Operating Expenses | 13.90M | 13.73M | 13.69M | 11.07M | 9.72M | 10.89M | 12.20M | 12.82M | 9.50M | 7.49M | 5.73M | 6.11M | 6.59M | 6.92M | 7.19M | 5.67M | 6.73M | 6.33M | 7.08M | 5.34M | 3.70M | 3.76M | 5.32M | 9.60M | 8.20M | 10.20M | 9.00M | 2.60M |
| Cost & Expenses | 16.93M | 17.63M | 17.68M | 12.89M | 12.37M | 16.08M | 16.52M | 17.00M | 12.55M | 11.12M | 8.92M | 9.17M | 9.60M | 10.45M | 10.65M | 8.35M | 9.63M | 9.37M | 9.60M | 7.76M | 5.70M | 5.74M | 7.29M | 12.51M | 9.04M | 19.80M | 10.60M | 2.60M |
| Interest Income | 0.00 | 54.61K | 16.36K | 6.71K | 1.54K | 7.45K | 9.30K | 1.29K | 3.84K | 5.06K | 115.00 | 34.00 | 35.00 | 587.00 | 3.15K | 9.02K | 0.00 | 87.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 54.61K | 16.36K | 18.08K | 0.00 | 0.00 | 0.00 | 1.29K | 0.00 | 2.67K | 70.80K | 178.97K | 131.84K | 95.14K | 154.03K | 116.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 150.77K | 144.38K | 128.93K | 130.28K | 256.47K | 881.29K | 573.15K | 163.37K | 97.38K | 95.84K | 96.12K | 95.13K | 105.39K | 128.64K | 126.39K | 127.24K | 148.91K | 118.76K | 118.15K | 101.92K | 335.22K | 417.99K | 435.18K | 718.62K | 732.86K | 500.00K | 300.00K | 200.00K |
| EBITDA | -6.96M | -8.68M | -7.30M | -7.36M | -3.90M | -5.58M | -4.66M | -6.35M | -2.96M | -694.34K | 1.18M | -596.20K | -1.24M | -572.20K | -2.10M | -1.73M | -3.24M | -3.52M | -3.13M | -2.91M | -1.40M | -1.25M | -2.77M | -6.12M | -5.45M | -10.50M | -7.20M | -2.10M |
| EBITDA Ratio | -70.78% | -98.61% | -70.89% | -135.31% | -1.28% | -41.97% | -41.32% | -60.59% | -31.18% | -15.48% | 2.68% | -6.89% | -11.83% | -7.72% | -22.50% | -33.97% | -53.23% | -63.09% | -62.63% | -61.17% | -35.17% | -32.04% | -69.12% | -103.48% | -162.54% | -123.86% | -262.07% | -766.67% |
| Operating Income | -7.11M | -8.83M | -7.38M | -7.45M | -4.00M | -8.00M | -5.23M | -6.51M | -3.06M | -790.18K | 1.09M | -520.35K | -1.22M | -700.84K | -2.10M | -1.73M | -3.24M | -3.52M | -3.25M | -3.01M | -1.73M | -1.67M | -3.20M | -6.84M | -6.18M | -11.00M | -7.70M | -2.30M |
| Operating Income Ratio | -72.31% | -100.24% | -71.60% | -137.08% | -47.75% | -83.14% | -46.40% | -62.14% | -32.20% | -7.65% | 10.85% | -6.02% | -14.60% | -7.19% | -24.61% | -26.10% | -50.70% | -60.28% | -50.47% | -63.31% | -43.61% | -40.98% | -78.18% | -120.48% | -216.49% | -125.00% | -265.52% | -766.67% |
| Total Other Income/Expenses | 125.53K | 54.61K | 259.82K | -18.08K | -3.64M | 215.00 | 4.37K | -3.80K | -1.51K | -907.81K | 378.23K | -349.95K | -258.50K | 86.33K | 573.43K | 541.13K | 301.55K | 370.52K | 492.87K | 11.34K | 0.00 | 53.93K | 64.49K | -246.28K | -807.60K | 400.00K | 0.00 | 200.00K |
| Income Before Tax | -6.98M | -8.77M | -7.12M | -7.47M | -7.64M | -8.00M | -5.23M | -6.52M | -3.06M | -1.70M | 1.46M | -870.31K | -1.35M | -519.96K | -2.16M | -1.08M | -2.94M | -3.15M | -2.27M | 0.00 | 0.00 | -1.62M | -3.14M | -7.08M | -6.99M | -10.60M | -7.50M | -2.10M |
| Income Before Tax Ratio | -71.04% | -99.62% | -69.08% | -137.41% | -91.27% | -83.13% | -46.36% | -62.18% | -32.22% | -16.43% | 14.63% | -10.06% | -16.12% | -5.33% | -25.23% | -16.31% | -45.98% | -53.94% | -35.26% | 0.00% | 0.00% | -39.66% | -76.60% | -124.82% | -244.77% | -120.45% | -258.62% | -700.00% |
| Income Tax Expense | 0.00 | -66.74K | 333.00 | 15.50K | 18.13K | 23.99K | 19.09K | -19.10K | 36.16K | 9.51K | -843.94K | 7.95K | 258.50K | -86.33K | -573.43K | -541.13K | -301.55K | -370.52K | -413.94K | -11.34K | 680.86K | 770.64K | 791.16K | 673.22K | 790.58K | -300.00K | -300.00K | -400.00K |
| Net Income | -6.93M | -8.71M | -7.12M | -7.49M | -7.66M | -7.43M | -5.19M | -5.95M | -5.47M | -1.70M | 1.46M | -870.31K | -1.48M | -614.51K | -1.53M | -1.19M | -2.94M | -3.15M | -2.75M | -3.00M | -2.41M | -2.44M | -3.99M | -7.51M | -6.97M | -10.70M | -7.40M | -1.90M |
| Net Income Ratio | -70.51% | -98.87% | -69.09% | -137.69% | -91.49% | -77.24% | -45.97% | -56.73% | -57.60% | -16.47% | 14.63% | -10.06% | -17.69% | -6.30% | -17.90% | -17.93% | -45.98% | -53.94% | -42.81% | -63.08% | -60.75% | -59.90% | -97.51% | -132.35% | -244.17% | -121.59% | -255.17% | -633.33% |
| EPS | -0.10 | -0.12 | -0.10 | -0.12 | -0.17 | -0.21 | -0.16 | -0.22 | -0.26 | -0.08 | 0.09 | -0.05 | -0.10 | -0.04 | -0.11 | -0.09 | -0.24 | -0.27 | -0.25 | -0.33 | -0.52 | -0.59 | -1.07 | -2.15 | -2.40 | -3.66 | -3.63 | -1.29 |
| EPS Diluted | -0.10 | -0.12 | -0.10 | -0.12 | -0.17 | -0.21 | -0.16 | -0.22 | -0.26 | -0.08 | 0.08 | -0.05 | -0.10 | -0.04 | -0.11 | -0.09 | -0.24 | -0.27 | -0.25 | -0.33 | -0.52 | -0.59 | -1.07 | -2.15 | -2.40 | -3.66 | -3.63 | -1.29 |
| Weighted Avg Shares Out | 72.78M | 70.61M | 68.83M | 63.06M | 45.74M | 35.30M | 32.70M | 26.97M | 21.03M | 20.06M | 17.13M | 16.08M | 15.17M | 14.82M | 13.39M | 12.67M | 12.14M | 11.79M | 11.01M | 9.15M | 4.67M | 4.16M | 3.71M | 3.50M | 2.91M | 2.92M | 2.04M | 1.47M |
| Weighted Avg Shares Out (Dil) | 72.78M | 70.61M | 68.83M | 63.06M | 45.74M | 35.30M | 32.70M | 26.97M | 21.43M | 20.06M | 17.48M | 16.08M | 15.17M | 14.82M | 13.39M | 12.67M | 12.14M | 11.79M | 11.01M | 9.15M | 4.67M | 4.16M | 3.71M | 3.50M | 2.91M | 2.92M | 2.04M | 1.47M |
Milestone Scientific projects 85% rise in 2021 revenue to more than $10M as divisions gain traction
Milestone Scientific Inc (NYSE:MLSS). has prepared investors for an 85% increase in revenue for its 2021 financial year as its dental and medical divisions continue to gain traction.
Milestone Scientific to Present at the H.C. Wainwright BioConnect 2022 Conference
ROSELAND, N.J., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Arjan Haverhals, Chief Executive Officer of Milestone Scientific, will be presenting...
Milestone Scientific commences sales of its CompuFlo Epidural disposables with prominent pain clinic in North Carolina
Milestone Scientific Inc. announced that it has commenced sales of its CompuFlo Epidural disposables with a prominent pain clinic in North Carolina. In a statement, the company said leading physician Dr. Harsh Govil, whose practice is based in Statesville, has begun...
Milestone Scientific announces purchase of its CompuFlo Epidural and CathCheck Verification System disposables at two leading hospitals
Milestone Scientific Inc. (NYSE:MLSS) announced the purchase of its CompuFlo Epidural and CathCheck Verification System disposables from two additional leading hospitals. The company added that the new orders will help expand its geographic footprint.
Milestone Scientific inks deal with Andau Medical to distribute STA Single Tooth Anesthesia System in the US and Canada
Milestone Scientific Inc (NYSE:MLSS) has announced an agreement with medical and dental device company Andau Medical to distribute Milestone's STA Single Tooth Anesthesia System in the US and Canada. “We initially began our collaboration with Andau around our CompuFlo Epidural Instrument in Canada,” Milestone Scientific CEO...
Milestone Scientific announces sale of its CompuFlo Epidural and CathCheck Verification System disposables to a Northeast teaching hospital
Milestone Scientific Inc (NYSE:MLSS) said that following a successful trial, it has signed an agreement for the purchase of its CompuFlo Epidural and CathCheck Verification System disposables with a major Northeast teaching hospital. “We are honored to announce the adoption...
Milestone Scientific says recognized pain management expert Dr Miguel de la Garza has adopted its CompuFlo Epidural instrument
Milestone Scientific Inc (NYSE:MLSS) has announced that Dr Miguel de la Garza, a recognized expert in pain management, has begun incorporating the company's CompuFlo Epidural instrument into his practice for pain management. The move follows approval by Surgery Partners, one of the...
Milestone Scientific Inc. (MLSS) CEO Arjan Haverhals on Q3 2021 Results - Earnings Call Transcript
Milestone Scientific Inc. (MLSS) CEO Arjan Haverhals on Q3 2021 Results - Earnings Call Transcript
Milestone Scientific, Inc. (MLSS) Reports Q3 Loss, Lags Revenue Estimates
Milestone Scientific, Inc. (MLSS) delivered earnings and revenue surprises of -50.00% and -6.31%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Milestone Scientific, the pressure sensing medtech group, enjoying revenue and cash flow growth
Revolutionizing injections for doctors and patients CompuFlo instruments provide feedback to distinguish tissue types for precise location guidance Establishing relationships with world-class global partners What Milestone Scientific Inc does: Milestone Scientific Inc (NYSEAMERICAN:MLSS) is a medical device research and development...
Source: https://incomestatements.info
Category: Stock Reports